Press RH, et al. - Researchers sought for targeted next-generation sequencing results and molecularly based outcomes for patients with lung adenocarcinoma (AC)-brain metastases (BMs) treated with radiotherapy. They reviewed the records of 132 patients with AC-BMs treated at Emory University from September 2008 to August 2016 with successful next-generation sequencing. Tumor protein 53 (TP53) (60%), KRAS (29%), epidermal growth factor receptor (EGFR) (20.5%), phosphatase and tensin homolog (PTEN) loss (15.5%), and MET amplification (13%) were identified as the most common aberrations. An increased risk of salvage WBRT was observed in relation to KRAS mutation, anaplastic lymphoma kinase (ALK) rearrangement, and having ≥ 6 BMs among patients treated with stereotactic radiosurgery alone. An increased risk of distant brain failure (DBF) was reported in relation to PTEN loss, whereas EGFR and ALK aberrations were related to a decreased risk of local disease recurrence.